Figure 7. Integrin-modulating therapy improves Treg cell function and ameliorates inflammation.

(A and B) Percentages of splenic CD4⁺, CD8⁺ (A), and Treg cells (B) from male Tln1^fl/flFoxp3^Cre mice treated with β1aAb (9EG7) or isotype control administered every 5 days for 6 weeks; n=4. (C) Percentages of CD4⁺ and CD8⁺ T cells expressing CD69 in β1aAb- or isotype-treated Tln1^fl/flFoxp3^Cre mice; displayed cells were gated on CD4⁺ or CD8⁺ events; n=4. (D) IFNγ and TNFα expression by splenic CD4⁺ (left) and CD8⁺ (right) T cells in β1aAb- or isotype-treated Tln1^fl/flFoxp3^Cre mice; displayed cells were gated on CD4⁺CD44^hi or CD8⁺CD44^hi events; n=4. (E and F) IL-2Rα expression in gated Treg cells from β1aAb- or isotype-treated Tln1^fl/flFoxp3^Cre mice as a percentage of Foxp3⁺ cells (E) and on a per cell basis (F); n=4. (G) Suppression by sorted talin-deficent Treg cells from β1aAb- or isotype-treated Tln1^fl/flFoxp3^Cre mice at decreasing Tconv:Treg cell ratios, measured at 72 hours; cultures were treated daily with β1aAb or isotype control. (H) Suppression by sorted talin-deficent Treg cells from β1aAb- or isotype-treated Tln1^fl/flFoxp3^Cre/wt mice at decreasing Tconv:Treg cell ratios, measured at 72 hours; cultures were treated daily with β1aAb or isotype control. (I) Suppression by sorted GFP⁺ Treg cells from β1aAb- or isotype-treated Foxp3^GFP mice at decreasing Tconv:Treg cell ratios, measured at 72 hours; cultures were treated daily with β1aAb or isotype control. (J) Proliferation of non-Treg Tconv cells isolated from β1aAb- or isotype-treated Foxp3^GFP mice based on CFSE dilution. Data are mean ± SEM and representative of at least 2 independent experiments. *, P < 0.05; **, P <0.01, *** P <0.005, unpaired Student’s t-test.